Christoph Lengauer

[Bill Clinton @BillClinton]

Over the course of a lifetime, we face only a few moments where the decisions we make and the actions we take will shape our history for years to come.  This is one of them.

[Christoph Lengauer @c_lengauer]

https://t.co/bHXSdjMGH9

[Christoph Lengauer @c_lengauer]

https://t.co/cd5yqycOOr

[MOMA Therapeutics @moma_tx]

We're pleased to share that we’ve dosed the first patient in the Phase 1 trial of MOMA-341, a potent oral Werner helicase inhibitor discovered with our KNOMATIC™ platform, for advanced MSI-H/dMMR tumors. Read more: https://t.co/3qYkp38Tqx

[Henrietta Lacks Legacy Group @HLacksLG]

Cervical Cancer Awareness Month: How Henrietta Lacks' cells changed the medical world https://t.co/Vfh1D873lK

[Christoph Lengauer @c_lengauer]

Small teams can be powerful!

[Christoph Lengauer @c_lengauer]

https://t.co/GGmJXFcgsA

[Christoph Lengauer @c_lengauer]

Glad I played a small part in this: https://t.co/Ln5wXGgLXH

[MOMA Therapeutics @moma_tx]

We’re heading to this year’s #ENASymp24 on Molecular Targets and #Cancer Therapeutics in Barcelona, Spain! Our Vice President, Biology and Translational Sciences, Erica Evans will be there to present a poster on our lead candidate, MOMA-313. https://t.co/8cJLUXzHz8

[Premier League @premierleague]

You won’t find many better ways to seal a hat-trick than this free-kick from Cole Palmer 😮‍💨

[MOMA Therapeutics @moma_tx]

The 1st patient has been dosed in the Phase 1 clinical trial of MOMA-313, a novel, highly potent & selective oral POLq helicase inhibitor, & we've selected our 2nd development candidate, MOMA-341, an oral Werner helicase inhibitor. Read & learn more: https://t.co/ZfPnYoLJJs

[MOMA Therapeutics @moma_tx]

Happy 4th birthday, MOMA! 🎉 we're so grateful for this journey - from humble beginnings to advancing our lead programs. Thank you to our team, partners, and supporters - You all have been instrumental in our growth and success. Here's to four years of MOMA and many more! 🎂

[Pearl Freier @PearlF]

Congrats to Novartis alum @TheDawnBell who is CEO of a new biotech startup, Antila Bioscience, developing long-acting biologics for patients w/severe cardiovascular disease & they raised $12M seed backed by Curie Bio (@c_lengauer, @zachweinberg) & F-Prime. Public update below:

[Christoph Lengauer @c_lengauer]

@zachweinberg And he is only 76

[Vishal Gulati (I back scientists) @VishalGulati_]

It's official. Insulin is cheaper than water

[Goose Data (wa/wa) @GooseData]

Ready for the "let's move JPM out of SF takes" 🙄

#JPM2024 #Cope #JPM24

[Thilo Schroeder @schroederthilo]

@moma_tx and @Roche join forces to go after new targets in oncology. Congrats to both teams on executing this exciting partnership!

[Cancer Research Horizons @CR_Horizons]

🤝 Today we welcome @annalisajenkins and @c_lengauer to our board.

With over 50 years of #biopharma experience between them, we look forward to their valuable help in delivering more #cancer treatments to patients faster.

Read more 👉 https://t.co/gzPcI7jQd4

[FC Red Bull Salzburg @RedBullSalzburg]

WINTERKÖNIG! ✅